With the recent launches of Physical Analyzer Ultra Series and Cellebrite Premium in SaaS mode, Cellebrite offers a powerful end-to-end collection and examination offering for digital investigations
PETAH TIKVA, Israel and TYSONS CORNER, Va., June 30, 2022 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in digital intelligence (DI) solutions for the public and private sectors, today announced the general availability of the Cellebrite Physical Analyzer Ultra Series (PA Ultra Series), the next generation of PA and the de facto industry standard for digital data review.
PA Ultra Series is a revolutionary solution that enables investigators to uncover key pieces of relevant digital evidence and examine digital data more efficiently, to help secure more convictions, speed up justice and close cases faster. The PA Ultra Series will significantly enhance Cellebrite’s Collection & Review offerings as part of the Digital Intelligence suite of solutions.
The PA Ultra Series will allow investigative teams to take advantage of an upgraded solution capable of processing a higher volume of computer, cloud and mobile data, open cases without having to analyze the data and take into Loads multiple cases and evidence per device with enhanced location data. from a new customizable dashboard. PA Ultra will also enable data enrichment for cryptocurrency, ranging from major blockchain data platforms to transaction tracking.
Ronnen Armon, Chief Product and Technology Officer, said, “The PA Ultra Series transforms PA data processing, decoding and reporting capabilities. We are confident that our continued innovation will enable examiners and law enforcement to make more efficient and insightful investigative decisions that will uncover the truth and achieve more convictions.
Additionally, after successful beta testing and preview preview, the SaaS version of Cellebrite Premium, an industry-leading advanced access solution, is now available to customers. With the general release of the PA Ultra series and the general availability of a SaaS version of Cellebrite Premium, Cellebrite has strengthened its position as a global leader in the digital intelligence market. The company provides a comprehensive collection and review technology stack to its public and private sector customers, dramatically increasing our customers’ ability to analyze data in surveys and manage this process in the cloud.
For more information on the Cellebrite PA Ultra Series, please visit https://cellebrite.com/en/pa-ultra.
For more information on Cellebrite Premium-as-a-Service, please visit: https://cellebrite.com/en/premium-as-a-service/.
Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, expedite justice and preserve privacy in communities around the world. We are a global leader in digital intelligence solutions for the public and private sectors, enabling organizations to master the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and enterprises worldwide, Cellebrite’s digital intelligence platform and solutions are transforming the way clients collect, review, analyze and manage survey data sanctioned by law. To find out more, visit www.cellebrite.com, https://investors.cellebrite.comor follow us on Twitter at @Cellebrite.
Caution Regarding Forward-Looking Statements
This document contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “forecast”, ” intention, “Seek”, “target”, “anticipate”, “will”, “appear”, “approximate”, “plan”, “could”, “possible”, “potential”, “believe”, “could”, “predict”, “should”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and others similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information. Such forward-looking statements regarding revenues, earnings, performance, strategies, prospects and other aspects of the ac Cellebrite’s performance are based on current expectations which are subject to risks and uncertainties. A number of factors could cause actual results or results to differ materially from those indicated by these forward-looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with ever-changing technological advances and industry standards; Cellebrite’s material dependence on acceptance of its solutions by law enforcement and government agencies; Actual or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s inability to maintain the productivity of sales and marketing personnel, including with respect to hiring, onboarding and retention of personnel; uncertainties regarding the impact of macroeconomic and/or global conditions, including COVID-19 and military actions involving Russia and Ukraine; intense competition in all of Cellebrite’s markets; inadvertent or deliberate misuse of Cellebrite solutions; political and reputational factors relating to Cellebrite’s business or operations; risks relating to market opportunity estimates and market growth forecasts; Cellebrite’s ability to successfully manage its growth; risks associated with Cellebrite’s credit facilities and liquidity; Cellebrite’s reliance on third party suppliers for certain components, products or services; challenges associated with large transactions and the long sales cycle; risks that Cellebrite’s customers will not meet their contractual or payment obligations; risks associated with a significant portion of Cellebrite’s business from government customers around the world; risks relating to Cellebrite’s intellectual property; security vulnerabilities or defects, including cyberattacks, breaches, failures or disruptions of computer systems; mishandling or perceived mishandling of sensitive or confidential information; complex and changing regulatory environments relating to Cellebrite’s operations and solutions; the regulatory constraints to which we are subject; the risks associated with different corporate governance requirements applicable to Israeli companies and the risks associated with being a foreign private issuer and an emerging growth company; market volatility in Cellebrite’s stock price; change tax laws and regulations; risks associated with joint ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, business compliance, anti-money laundering and economic sanctions laws and regulations; risks relating to the suitability of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section entitled “Risk Factors” of Cellebrite’s Annual Report on Form 20-F filed with the SEC on March 29, 2022 and in other documents filed by Cellebrite with the United States Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, if circumstances change, except as required by applicable securities and other laws. .
Director of Public Relations and Institutional Communication
VP Investor Relations
+972 73 394 8440